Skip to main content
Daniel Javitt, MD, Psychiatry, New York, NY

DanielC.JavittMDPhD

Psychiatry New York, NY

Psychopharmacology

Director, Division of Experimental Therapeutics Director, Columbia Conte Center for Schizophrenia Research Professor of Psychiatry and Neuroscience Columbia University College of Physicians and Surgeons New York, NY Director, Division of Schizophrenia Research Nathan Kline Institute for Psychiatric Research Orangeburg, NY

Dr. Javitt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Javitt's full profile

Already have an account?

  • Office

    1051 Riverside Dr
    Unit 21
    New York, NY 10032
    Phone+1 212-543-5475
    Fax+1 212-543-5668

Education & Training

  • Montefiore Medical Center/Albert Einstein College of Medicine
    Montefiore Medical Center/Albert Einstein College of MedicineResidency, Psychiatry, 1986 - 1987
  • Montefiore Medical Center/Albert Einstein College of Medicine
    Montefiore Medical Center/Albert Einstein College of MedicineResidency, Psychiatry, 1984 - 1986
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 1983

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1984 - 2025
  • MD State Medical License
    MD State Medical License 2009 - 2010
  • American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Multicenter Study of Ketamine Effects on Functional Connectivity: Large Scale Network Relationships, Hubs and Symptom Mechanisms  
    Ragy R Girgis, Richard J Maddock, John D Ragland, Daniel C Javitt, Cameron S Carter, Joshua T Kantrowitz, Jeffrey Lieberman, John H Krystal, Lawrence S Kegeles, Willia..., ScienceDirect
  • American Psychiatric Association Publishing  
    Cheryl M Corcoran, Daniel C Javitt, National Institutes of Health
  • Sensory and Cross-Network Contributions to Response Inhibition in Patients with Schizophrenia  
    Daniel C Javitt, Matthew J Hoptman, ScienceDirect

Press Mentions

  • Pharma Consortium Publishes Results of Large EEG/ERP Biomarker Study in Subjects with Schizophrenia and Healthy Volunteers
    Pharma Consortium Publishes Results of Large EEG/ERP Biomarker Study in Subjects with Schizophrenia and Healthy VolunteersMarch 16th, 2023
  • CUIMC Update - Sept. 13, 2021
    CUIMC Update - Sept. 13, 2021September 13th, 2021
  • NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. And Big Rock Partners Acquisition Corp (Nasdaq:BRPA)
    NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. And Big Rock Partners Acquisition Corp (Nasdaq:BRPA)May 25th, 2021
  • Join now to see all

Grant Support

  • Early Cortical Processing In SchizophreniaNational Institute Of Mental Health2003–2012
  • Multimodal Assessment Of Sensory Processing Dysfunction In SchizophreniaNational Institute Of Mental Health2011
  • AdministrativeNational Institute Of Mental Health2011
  • The Conte Center For Schizophrenia ResearchNational Institute Of Mental Health2010–2011
  • The Conte Center For Schizophrenia ResearchNational Institute Of Mental Health2009–2010
  • Multimodal Assessment Of Sensory Processing Dysfunction In SchizophreniaNational Institute Of Mental Health2009–2010
  • AdministrativeNational Institute Of Mental Health2009–2010
  • Sensory Processing Dysfunction In Neuropsychiatric IllnessNational Institute Of Mental Health2008–2010
  • Phencyclidine Abuse &Psychosis: Biomedical MechanismsNational Institute On Drug Abuse2007–2010
  • Pk/Pd, Dose Finding And Adjunctive Treatment StudiesNational Institute Of Mental Health2005–2009
  • D-Serine Treatment Of SchizophreniaNational Institute Of Mental Health2005–2009
  • Methods For Sensory Assessment In SchizophreniaNational Institute Of Mental Health2008
  • Dopamine In A Primate Model Of Glutamate HypofunctionNational Institute Of Mental Health2004–2008
  • Neurophysiological NMDA Dysfunction In SchizophreniaNational Institute Of Mental Health1997–2006
  • Phencyclidine Abuse And Psychoses: Biomedical MechanismsNational Institute On Drug Abuse2001–2005
  • Mechanisms Of Cognitive Dysfunction In SchizophreniaNational Institute Of Mental Health2001–2005
  • Neuroanatomic Basis Of Cognitive ERP Deficit In SchizophFogarty International Center2001–2003
  • Treatment Of Negative Symptoms And Cognitive ImpairmentsNational Institute Of Mental Health2000–2003
  • High-Density ERP Mapping &FmriNational Center For Research Resources2002
  • Early Cortical Processing In SchizophreniaNational Institute Of Mental Health1998–2002
  • Phencyclidine Abuse And Psychosis--Biomedical MechanismsNational Institute On Drug Abuse1998–2000
  • Intracortical Mechanisms Of COG Dysfunction In SchizophrNational Institute Of Mental Health1997–1999
  • Early Cortical Processing In SchizophreniaNational Institute Of Mental Health1996–1997
  • Assessment Of Glycine Treatment In SchizophreniaNational Institute Of Mental Health1996–1997
  • Phencyclidine Abuse &Psychosis--Biomedical MechanismsNational Institute On Drug Abuse1995
  • Early Cortical Processing In SchizophreniaNational Institute Of Mental Health1995
  • Early Cortical Processing In SchizophreniaNational Institute Of Mental Health1993–1995
  • NMDA Receptors In Processing Contingent Aep GenerationNational Institute Of Mental Health1990–1991
  • Phencyclidine Psychopharmacology--SchizophreniaNational Institute Of Mental Health1986–1990